Sign in to fuzzto save your conversations, follow your research and come back anytime.
The Quarter story
The two most recent quarterly results, compared side-by-side.
Consolidated profits surge as capacity utilization jumps and Innoxel turns profitable.
General Block capacity utilization rose from 48.5% to 70.0% in Q2 FY27 — assets are being used more efficiently
Domestic tender order book fell from ₹119 Cr to ₹65.6 Cr in Q2 FY27 — local demand pipeline is contracting
Consolidated EBITDA improved from -₹0.09 Cr to ₹23.4 Cr in Q2 FY27 — profitability turned sharply positive
Gross margin declined from 44.1% to 34.8% between Q2 FY25 and Q2 FY27 — input costs or pricing pressure is squeezing margins
Innoxel Lifesciences EBITDA margin jumped from -8.5% to 32.9% in Q2 FY27 — subsidiary operations are now highly profitable
Total order book grew from ₹171 Cr to ₹184 Cr in Q2 FY27 — demand pipeline remains stable
Company insights, generated from the most recent coverage.
The FY26 standalone revenue fall to ₹234 Cr from ₹304 Cr was partly self-inflicted — deferred export tenders, a deliberate exit from low-margin volume and downtime from plant upgrades. A shrinking top line here is not automatically lost share, so read standalone declines against margin intent before assuming demand weakness.
CDMO is now 20.4% of FY26 consolidated revenue (₹72.3 Cr of ₹355 Cr) versus trading at 17.5% (₹62.2 Cr) — contract manufacturing has already overtaken the low-margin trading arm, so the mix shift toward higher-value work is visible in the segment numbers, not just in management commentary.
FY26 consolidated revenue of ~₹355 Cr with two straight loss years (FY25 -₹43.7 Cr, FY26 -₹27.3 Cr) and negative ROE (-8.4%) and ROCE (-1.4%) puts it firmly in the niche, sub-scale bucket of Indian pharma. At a ₹1,318 Cr market cap on a ₹1,318 Cr cap / no meaningful earnings base, the stock is being valued on the Innoxel and Varenyam Bio optionality, not on current profits.